Date: 2013-05-29
Type of information: Company acquisition
Acquired company: Okairos (Switzerland)
Acquiring company: GSK (UK)
Amount: €250 million
Terms: * On May 29, 2013, GSK has announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.
Okairos has developed a novel vaccine platform technology which is expected to play an important role in GSK’s development of new prophylactic vaccines as well as new classes of therapeutic vaccines. Okairos’ technology complements GSK’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines. The deal also includes a small number of early stage assets.
Under the terms of the transaction, GSK will take full ownership of the company and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus (RSV), hepatitis C virus (HCV), malaria, tuberculosis, ebola and HIV, supplementing the company’s existing vaccines pipeline.
Details:
Related: Vaccines
